NEP-GROUP
16.2.2024 09:16:29 CET | Business Wire | Press release
NEP Group, the leading worldwide media technology partner for live sports and entertainment, announced today that Lise Heidal has been appointed President, NEP Europe for NEP Broadcast Services, effective 1 April. Based in Norway, Heidal will set the strategy, priorities and focus areas for nine countries in Northern, Central and Southern Europe, as well as in the UK and Ireland, to lead the future planning of NEP’s broadcast services businesses.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240216806377/en/
Industry veteran Lise Heidal has been appointed President, NEP Europe for NEP Broadcast Services. She will set the strategy, priorities and focus areas for all countries in Northern, Central and Southern Europe, as well as in the UK and Ireland, to lead the future planning of NEP’s broadcast services businesses. (Photo: Business Wire)
With over 25 years of multifaceted experience in the media, telecom, and consulting industries, Heidal stands out as a pragmatic leader committed to driving operational excellence, business transformation and strategic innovation. Known as someone committed to building great teams with a genuine interest in the people she works with, Heidal’s approach combines strategic vision and operational expertise, whilst fostering a culture of accountability. Most recently she served 2,5 years as the VP of Production at TV 2, the largest commercial broadcaster in Norway. Prior to that, she served as Managing Director of NEP Norway and led several global NEP initiatives that achieved continuous development and profitable growth from 2010 to 2021.
As part of the new European leadership team, Christer Pålsson has been named Chief Commercial Officer for Europe, reporting into Heidal. As CCO, Pålsson will be responsible for all commercial and sales activities across the region and work closely with NEP’s global sales team to align strategy and execution, including for major events worldwide. He brings with him extensive experience in business leadership, sales, client service, partnerships and operations for NEP in the Nordics, Central and Southern Europe. Prior to joining NEP, Pålsson was Head of International Sales for Mediatec Broadcasting company, which became a part of NEP in 2015.
To support this transition NEP is also pleased to announce that Jose (Tex) Teixeira will join NEP on 4 April initially as President for NEP Nordics, Central & Southern Europe. Teixeira brings with him over 30 years of sport broadcast experience delivering world-class live productions in Africa and New Zealand. A creative, loyal and energetic individual with a can-do spirit, he has specialised in content strategy and acquisition, programming and production, leading large teams, building dynamic environments and managing strategic relationships with rights holders, federations and suppliers across multiple territories throughout his career. He most recently served as Chief Content Officer for SuperSport and as their Interim CEO in 2023.
Rounding out the European senior leadership team, Arjan van Westerloo and Steve Jenkins will continue in their current roles as President, NEP The Netherlands, and President, NEP UK & Ireland, respectively.
Mike Werteen, Global President of NEP Broadcast Services, said: “Combining our UK and European businesses under a single, dynamic and experienced leadership team is an exciting step forward. Having such a powerful group in place enables us to achieve our vision to be the leading global media services provider in live sports and entertainment. Under Lise’s direction, supported by the foundations that all European and UK team members have put into place, I’m confident we will be able to harness all of the talent, synergies, sales and employee career opportunities across these important markets.”
Lise Heidal said: "I am deeply honored to accept the position as lead of the NEP Broadcast Services European organization. It is a privilege to have the opportunity to work with a team of such dedicated and talented individuals. I am fully committed to enhancing our collaborative efforts across Europe, to serving our clients, and to continue building on our shared successes."
While continuing to manage the day-to-day business, the first priority for the European leadership team will be to drive increased collaboration and process improvements for the region as part of the company’s 2024 goals and longer-term plans.
For more information about NEP, visit www.nepgroup.com.
About NEP
You have a vision. We see it, too. With a worldwide network of experts and cutting-edge technology, our unique Global Production Ecosystem empowers content creators and rights holders to tell stories in breakthrough ways. We're built on 35 years of trusted experience across broadcast, live event, and virtual production to deliver the solutions you need—anytime, anywhere.
Headquartered in the United States, NEP has operations in 25 countries with over 5,000 employees. Together, we have supported productions in over 100 countries on all seven continents, and we’re still growing. Learn how we help our clients bring content to life at nepgroup.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240216806377/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
